Table 2 Comparison of clinical features between the training and internal validation cohorts.
Variables | Training cohort | Internal validation cohort | p-value |
|---|---|---|---|
Age (years) | 69.5 ± 9.4 | 69.3 ± 7.2 | 0.903 |
tPSA | 16.6 (9.3, 31.5) | 15.4 (8.0, 33.5) | 0.393 |
fPSA | 1.6 (0.9, 4.8) | 1.9 (0.9, 5.7) | 0.609 |
fPSA/tPSA | 0.13 (0.07, 0.23) | 0.15 (0.11, 0.25) | 0.119 |
PV | 55.5 (41.6, 75.8) | 64.25 (47.91,92.07) | 0.098 |
TZV | 28.2 (16.0, 45.7) | 35.86 (18.0, 49.2) | 0.310 |
PZV | 26.2 (18.5, 34.6) | 30.0 (18.6, 47.0) | 0.086 |
PSAD | 0.31 (0.15, 0.62) | 0.22 (0.12, 0.44) | 0.098 |
TZ-PSAD | 0.65 (0.28, 1.79) | 0.42 (0.24, 1.19) | 0.141 |
PZ-PSAD | 0.8 (0.36, 1.7) | 0.53 (0.26, 1.53) | 0.079 |
PI-RADS | 0.754 | ||
1 | 5 (4.2%) | 0 | |
2 | 15 (12.6%) | 9 (17.3%) | |
3 | 44 (37%) | 18 (34.6%) | |
4 | 23 (19.3%) | 16 (30.8%) | |
5 | 32 (26.9%) | 9 (17.3%) | |
Pathologic diagnosis | 0.995 | ||
Benign | 71 (59.7%) | 31 (59.6%) | |
Malignant | 48 (40.3%) | 21 (40.4%) |
